2023 World Conference on Lung Cancer (Posters)-P2.06. PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)

P2.06. PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901) - PDF(Abstract)

Back to course

Pdf Summary

The study discussed in this session compared the efficacy and safety of sintilimab and pembrolizumab, both PD-1 inhibitors, in the treatment of untreated advanced non-small cell lung cancer (NSCLC). The study included patients with high PD-L1 expression and randomized them to receive either monotherapy with sintilimab or pembrolizumab, or combination therapy with either drug plus chemotherapy. The primary endpoint was objective response rate (ORR), and secondary endpoints included disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety.<br /><br />By the cutoff date of October 31, 2022, a total of 71 patients were enrolled in the study, with 35 in the sintilimab arms and 36 in the pembrolizumab arms. The study met its primary endpoint, with 18 patients treated with sintilimab achieving a partial response. The ORR was 46.2% for sintilimab monotherapy, 54.5% for sintilimab combination therapy, 42.9% for pembrolizumab monotherapy, and 45.4% for pembrolizumab combination therapy. The median PFS was 6.9 months for sintilimab-treated patients and 8.1 months for pembrolizumab-treated patients. The median OS was 14.9 months for sintilimab-treated patients and 21.3 months for pembrolizumab-treated patients.<br /><br />Overall, sintilimab was found to be efficacious and well-tolerated in patients with untreated advanced NSCLC, regardless of PD-L1 expression. It showed similar efficacy and safety to pembrolizumab. However, grade 3 treatment-emergent adverse events (TEAEs) occurred more frequently in patients receiving combination therapy compared to monotherapy.<br /><br />This study provides valuable insights into the use of PD-1 inhibitors in the treatment of metastatic NSCLC and highlights the potential of sintilimab as a viable treatment option.

Asset Subtitle

Si-Yang Liu

Meta Tag

Speaker Si-Yang Liu

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

sintilimab

pembrolizumab

PD-1 inhibitors

non-small cell lung cancer

NSCLC

untreated advanced NSCLC

monotherapy

combination therapy

objective response rate

progression-free survival